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Caveolin-1 (CAV1) and caveolin 2 (CAV2) are the principal structural proteins of caveolae, sphingolipid and cholesterol-rich
invaginations of the plasma membrane involved in vesicular trafficking and signal transduction. Over the recent years there has been
controversy about their role in breast cancer and their suitability as markers of basal-like phenotype. Caveolin-1 and CAV2 protein
expression was assessed on a tissue microarray containing 880 unselected invasive breast cancer cases, by means of
immunohistochemistry. Caveolin-1 and CAV2 expression was observed in 13.4 and 5.9% of all breast cancer, respectively. Their
expression was strongly associated with high histological grade, lack of steroid hormone receptor positivity (ER and PR), and
expression of basal markers (basal cytokeratins, P63, P-cadherin). Furthermore, there was a significant association between CAV1 and
CAV2 expression and basal-like phenotype. On univariate analysis only CAV2 had a prognostic impact on breast cancer-specific
survival; however, this was not independent from other traditional markers on multivariate analysis. Our results demonstrate that
both CAV1 and CAV2 are associated with basal-like phenotype. Further studies are warranted to determine whether they play an
oncogenic role in basal-like/triple-negative breast cancer development or are just surrogate markers for this subgroup.
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Caveolae are special invaginated microdomains of the plasma
membrane found in the majority of mammalian cells and serve as
membrane organising centres. Three members of the caveolin
family (CAV1, CAV2, and CAV3) have been identified and they
play a pivotal role in intracellular trafficking of cellular
components and in signal transduction (Hnasko and Lisanti,
2003). Despite several studies on caveolins in cancer, especially
CAV1, their role in cancer development and progression is still
contentious.
Caveolin-1 and CAV2 genes map to chromosome locus 7q31.1
near the D7S522 genetic marker, which is a known fragile site
(FRA7G) (Engelman et al, 1998; Hayashi et al, 2001; Lee et al,
2002). Caveolin-1 was first thought to have tumour suppressor
properties (Razani et al, 2001a,b; Hnasko and Lisanti, 2003), based
on the finding of an arguable inactivating point mutation in CAV1,
the silencing of CAV1 gene expression by promoter hypermethyla-
tion in breast cell lines and prostate tumour samples (Engelman
et al, 1999; Hurlstone et al, 1999; Cui et al, 2001) and the apparent
downregulation of CAV1 in breast cancer (Chen et al, 2004; Park
et al, 2005). In recent years, there has been increasingly more
coherent data to suggest that CAV1 and CAV2 may also have
oncogenic properties in breast (Hurlstone et al, 1999; Pinilla et al,
2006; Van den Eynden et al, 2006; Savage et al, 2007, 2008),
prostate (Yang et al, 1998; Thompson et al, 1999), bladder
(Rajjayabun et al, 2001; Fong et al, 2003), oesophageal (Kato et al,
2002; Ando et al, 2007), thyroid, pancreatic, non-small cell and
squamous lung cancer (Kato et al, 2004; Sunaga et al, 2004).
Despite the controversy about the distribution of CAV1 and
CAV2 in normal and invasive breast cancer (Yang et al, 1998;
Hurlstone et al, 1999; Chen et al, 2004; Sagara et al, 2004; Park
et al, 2005; Van den Eynden et al, 2006), recent studies confirmed
the preferential expression of both genes and their proteins in
normal myoepithelial cells (Pinilla et al, 2006; Savage et al, 2007,
2008). Furthermore Savage et al, have recently reported high
prevalence of CAV1 and CAV2 expression in basal-like breast
carcinomas (Savage et al, 2007, 2008), and observed CAV1 gene
amplification in a small subgroup of basal-like breast cancers
(Savage et al, 2007, 2008). Moreover, these findings support Pinilla
et al who described an association between CAV1 expression and
sporadic basal-like breast cancers and familial BRCA1 tumours
(Pinilla et al, 2006).
Our aims in this study were (1) to assess CAV1 and CAV2
prevalence in a well-characterised series of 880 cases of invasive
breast carcinomas using high-throughput tissue microarray (TMA)
technology and immunohistochemistry; (2) to determine whether
CAV1 and CAV2 could be used as diagnostic markers to identify
basal-like subtypes of invasive breast cancers, and (3) to assess if
CAV1 and CAV2 have prognostic significance on the outcome of
patients with invasive breast cancer.
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Patient data
The tissue microarrays comprised a cohort of 880 consecutive
breast tumours from patients diagnosed between 1986–1998 and
entered into the Nottingham Tenovus Primary Breast Carcinoma
Series. Histological tumour types comprised 449 invasive ductal
carcinomas of no special type (NST), 182 tubular mixed
carcinomas, 25 medullary carcinomas, 83 lobular carcinomas, 28
tubular carcinomas, eight mucinous carcinomas, six cribriform
carcinomas, four papillary carcinomas, 29 mixed NST and lobular
carcinomas, 23 mixed NST and special type carcinomas, and six
miscellaneous tumours. Full details of the characterisation of the
TMA and the cohort of the patients are described elsewhere
(Elbauomy Elsheikh et al, 2007). Patient management was based
on tumour characteristics provided by the Nottingham Prognostic
Index (NPI) and hormone receptor status. Patients with an NPI
score p3.4 received no adjuvant therapy, those with a NPI score
43.4 received tamoxifen if oestrogen receptor (ER) positive:
(±Zoladex if pre-menopausal) or classical cyclophosphamide,
methotrexate and 5-fluorouracil if ER negative and fit enough to
tolerate chemotherapy (Madjd et al, 2005). Tumours were graded
according to a modified Bloom–Richardson scoring system
(Elston and Ellis, 1991) and size was categorised according to
the TNM staging criteria (Singletary and Connolly, 2006).
Nottingham Prognostic Index was calculated as previously
described (Galea et al, 1992). Survival data including disease-free
survival (DFS), metastasis-free survival (MFS) and breast cancer
specific survival (BCSS) were maintained on a prospective basis.
Disease-free survival and MFS were defined as the interval (in
months) from the date of the primary surgical treatment to the
first loco-regional or distant recurrence, respectively. Breast
cancer-specific survival survival was taken as the time (in months)
from the date of the primary surgical treatment to the time of
death from breast cancer. This study was approved by the
Nottingham Research Ethics Committee 2 under the title of
‘Development of a molecular genetic classification of breast
cancer’.
Immunohistochemical staining and scoring
Breast cancer tissue microarrays were prepared and immuno-
histochemically (IHC) stained for CAV1 and 2 as described
previously (Abd El-Rehim et al, 2004b, 2005a; Rakha et al, 2006;
Reis-Filho et al, 2006). Validation of both antibodies was
performed in previous studies (Savage et al, 2007, 2008). The
mouse monoclonal antibodies (2297, ref. 10 at 1:150 dilution and
clone 65 at a dilution of 1:50, both BD Transduction Labs,
Erembodegem, Belgium) were used for CAV1 and CAV2 staining,
respectively, following microwave heat-induced antigen retrieval
using DAKO antigen retrieval solution (pH 6.0) (DakoCytomation,
Glostrup, Denmark). Detection was achieved with the Envision kit
(Dako). Negative controls comprising omission of the primary
antibody and IgG-matched serum, were included in each IHC
run. Caveolin-1 and CAV2 immunohistochemical distribution on
tissue microarray sections was analysed by three of the authors
(ER, RS & AA), separately. Cases were classified as positive if any
membranous staining (with or without cytopalsmic reactivity) was
found. The analysis was performed blinded to the results of other
immunohistochemical markers and patients’ outcome. The
immunostaining, morphometric scoring using H-score, and
dichotomous categorisation of oestrogen receptor, progesterone
receptor, cytokeratin (Ck) 7/8, Ck 18, Ck 19, Ck 5/6, Ck 14, HER2,
EGFR, P63, E-cadherin and P-cadherin are described elsewhere
(Abd El-Rehim et al, 2004a,b, 2005b). On the basis of the
expression of HER2, ER, Ck 5/6 and EGFR, tumours were classified
according to the immunohistochemical panel proposed by Nielsen
et al (2004) and to triple-negative phenotype (TN), which was
immunohistochemically defined by the lack of expression of
oestrogen receptor (ER), progesterone receptor (PR) and HER2
(HER2) (Bauer et al, 2007; Carey et al, 2007; Rakha et al, 2007).
Statistical analysis
Statistical analysis was performed using SPSS 13.0 statistical
software. Median follow-up was defined as follow-up period for
those patients still alive and disease-free at their latest hospital
visit. All factors were used as dichotomous covariates in the
statistical analysis with the exception of grade, NPI and phenotypic
groups proposed by Nielsen et al (2004) that were divided into
three groups. Unweighted k agreement coefficient test was used to
assess agreement between observers of the same variables. To test
whether these variables differed according to clinicopathological
variables and biological markers the w
2 test and Fisher’s exact test
were used. All P-values were two-sided, and Po0.05 was
considered significant. Kaplan–Meier plots were used to visualise
the survival distribution. Differences in DFS, MFS and BCSS on the
basis of CAV1 and CAV2 expression were estimated using log-rank
test. Cox proportional hazards model was used to test the
statistical independence and significance of predictors on DFS,
MFS and BCSS.
RESULTS
Patient clinical outcome
Follow-up data were available for 547 out off 561 cases that showed
informative data for CAV1 or CAV2. Survival time ranged from 1
to 192 months (median – 86 months, mean – 81 months). During
this period, a total of 78 (13.9%) patients died from breast cancer.
Of the available cases, 106 (18.9%) cases were grade 1, 167 (29.8%)
cases were grade 2, and 274 (48.8%) were grade 3. At the time of
the primary diagnosis, 184 (32.8%) of the patients had lymph
node-positive disease, 375 (66.8%) had tumour size more than
2cm and distant metastases was observed in 87cases (15.5%).
The incidence of CAV1 and CAV2 expression in invasive
breast cancer
After excluding the uninformative TMA cores, which were either
lost, fragmented or did not have invasive tumour, 516 cases were
analysable for CAV1 and/or CAV2: CAV1, n¼461; CAV2, n¼410;
and both, n¼310. Caveolin-1 positivity was detected in 13.4%
whereas CAV2 was found in 5.9% of invasive breast cancer cases
(Table 1) (Figure 1). Coexpression of both CAV1 and CAV2
proteins was found in only 2.5% out of 310 cases where
informative data were available for both CAV1 and CAV2. A
statistically significant correlation between the expression of both
proteins was found (Po0.001). Good agreement was found
between observers regarding CAV1 and CAV2 scoring
(unweighted k score¼0.57879) (0.4678–0.6896).
Table 1 The frequency of CAV1 and CAV2 expressions in invasive
breast carcinoma
Number of
positive cases Percentage
Total
number
CAV1 62 13.4 461
CAV2 24 5.9 410
CAV1 and CAV2 8 2.5 310
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sFigure 1 Caveolin-1 and CAV2 expression in invasive duct carcinoma (IDC) of the breast. (A–C) CAV1 expression in Grade 3 IDC. (D–F) CAV1
positive expression in Grade1 IDC the arrow in (E) point to the associated DCIS component. (G–I) CAV1 negative expression in Grade 1 IDC. (J–L)
CAV2 positive expression in Grade3 IDC. (M–O) CAV2 negative expression in Grade 1 IDC. The arrows in (I and O) point to the positive stromal cells,
which represent an internal positive control for CAV1 and CAV2. (A, D, G, J and M original magnification  100, (B, E, H, K and N) original magnification
 200; (C, F, I, L and O) original magnification  400).
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variables and immunohistochemical markers
There was a significant positive correlation between CAV1
expression and high histological grade (P¼0.026), lack of ER
and PR expression (Po0.001 and 0.004, respectively). A significant
inverse correlation between expression of luminal cytokeratins
(Ck 7/8, Ck 18, and Ck 19) and positivity for CAV1 was found
(P¼0.003, 0.001, and 0.026, respectively). Furthermore, there was
a strong positive association between CAV1 and basal cytokeratin
(Ck5/6 and Ck14) (P¼0.004 and 0.038, respectively) expression, as
well as positivity for P63 and P-cadherin (Po0.001 and 0.007,
respectively). These results were reflected in the phenotypic groups
of breast cancer proposed by Nielsen et al (2004), where 40.5% of
CAV1 positive cases had a basal-like phenotype, whereas 41.1%
displayed a triple-positive phenotype (both Po0.001, Table 2).
Correlation between CAV2 and clinicopathological
variables and immunohistochemical markers
CAV2 expression was associated with poor prognostic parameters.
CAV2 expression was associated with high tumour grade
(P¼0.005), large tumour size (Po0.001) and poor Nottingham
prognostic index (P¼0.017). A strong inverse correlation was
found between lack of steroid hormone receptors ER, PgR, and AR
with positive expression of CAV2 (Po0.001, o0.001 and 0.039,
respectively). CAV2 positive breast cancers frequently expressed
basal markers, including Ck 5/6, Ck 14, p63 (Po0.001, 0.001 and
o0.001, respectively). CAV2 was more frequently negative in those
that lacked expression of luminal cytokeratins, including Ck 7/8
and Ck 18 (Pp0.001 and 0.022, respectively). An inverse
correlation between CAV2 and E-cadherin expression was found
(P¼0.034). As expected, CAV2 displayed a strong association with
Table 2 Correlation between expression of CAV1 and CAV2 in tumor cells and clinicopathological and immunohistochemical markers in invasive breast
cancer
CAV1 CAV2
Parameter Number of samples Negative Positive P-value Number of samples Negative Positive P-value
Grade 449 0.026 400 0.005*
1 78 6 72 1
2 126 14 111 2
3 186 39 193 21
Size 449 0.100 400 o0.001**
p2cm 236 36 238 6
42cm 154 23 138 18
LN 447 399 0.259
Negative 250 41 0.558 242 18
Positive 138 18 134 5
NPI 447 0.112 399 0.017*
Good 125 12 115 1
Moderate 202 39 203 18
Poor 61 8 58 4
Vascular invasion 442 1.000 319 0.369
No 270 42 250 14
Yes 113 17 117 10
ER 431 o0.001** 384 o0.001**
Negative 113 37 126 18
Positive 264 17 237 3
PR 429 386 o0.001**
Negative 117 38 0.004** 171 20
Positive 197 17 193 2
AR 408 0.140 364 0.039**
Negative 144 28 143 14
Positive 210 26 200 7
Ck7/8 445 0.003** 395 o0.001**
Negative 142 34 128 17
Positive 244 25 243 7
Ck18 402 0.026** 363 0.022**
Negative 97 24 92 11
Positive 250 31 250 10
Ck19 442 0.001** 391 0.161
Negative 75 23 65 7
Positive 310 34 303 16
Ck5/6 444 0.004** 396 o0.001**
Negative 296 34 298 8
Positive 89 25 74 16
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(Nielsen et al, 2004), where 66.7% of CAV2-positive cases were of
basal type whereas 58.1% displayed a triple-negative phenotype
(both Po0.001, Table 2).
CAV1 and 2 expressions in relation to patient outcome
Kaplan–Meier survival analysis did not reveal any association
between CAV1 expression and BCSS or DFS in the whole cohort.
However, there was a significant association between positive
CAV2 expression and shorter BCSS (P¼0.032) and a trend for
shorter metastasis-free survival (MFS, P¼0.07). Further sub-
grouping of the cohort revealed that in the ER-negative group of
patients CAV1 expression displayed a trend for longer DFS
(P¼0.069), whereas CAV2-positive cases showed a trend for
shorter BCSS (P¼0.053). The only significant relation between
CAV1 expression and poor outcome was observed in the low
tumour grade cohort of patients (Grade 1), where positive
expression of CAV1 was associated with shorter DFS (P¼0.013)
(Figure 2). Although these results are of interest, it should be noted
that this is a retrospective and exploratory analysis and the
number of patients with grade 1, CAV1-positive breast cancers was
rather limited. No statistically significant correlation was found
between expression of CAV1, CAV2 and CAV1 and/or CAV2 and
patient outcome (BCSS and DFS) in the group of chemotherapy-
treated patients and when only patients with triple-negative breast
cancers were analysed. On multivariate analysis, both proteins
were shown not to be independent prognostic factors for DFS and
BCSS.
DISCUSSION
Gene expression profiling has led to classification of breast cancers
into five groups: luminal A, luminal B, basal-like, HER2þ and
normal breast-like (Perou et al, 2000; Sorlie et al, 2001, 2003; van
de Rijn et al, 2002; Sotiriou et al, 2003; Nielsen et al, 2004) and
importantly these groups have prognostic and predictive implica-
tions. Basal-like tumours, which comprise approximately 15–20%
of breast cancers, were so named because their transcriptome
closely resembles that of myoepithelial/basal cells of normal breast.
The majority of basal-like tumours lack ER, PgR and HER2
expression (i.e. display a triple-negative phenotype) (Nielsen et al,
2004; Rouzier et al, 2005; Banerjee et al, 2006; Livasy et al, 2006;
Tan et al, 2007).
Previous studies using immunohistochemistry/immunofluores-
cence (Pinilla et al, 2006; Savage et al, 2007, 2008) and cDNA
arrays (Jones et al, 2004; Sagara et al, 2004) have demonstrated
that in ducts and lobules of normal breast, CAV1 and CAV2
expression is preferentially seen in myoepithelial and basal cells.
However, caveolins 1 and 2 are also abundantly expressed in
Table 2 (Continued)
CAV1 CAV2
Parameter Number of samples Negative Positive P-value Number of samples Negative Positive P-value
Ck14 434 0.038** 383 0.001**
Negative 302 39 293 12
Positive 74 19 66 12
P-Cadherin 354 0.007** 319 0.230
Negative 119 8 103 4
Positive 190 37 195 17
FGFR1 289 0.491 256 1.000
Negative 235 28 221 13
Positive 25 1 21 1
P63 445 o0.001** 397 o0.001**
Negative 378 50 365 17
Positive 9 8 8 7
E- cadherin 429 0.060 387 0.034
Negative 241 44 221 18
Positive 130 14 144 4
EGFR1 314 215 37 0.084 279 0.74
Negative 54 8 212 13
Positive 52 2
Nielsen groups 367 o0.001* 320 o0.001*
Her2 46 8 44 3
Luminal 243 17 221 2
Basal-like 36 17 40 10
TN 430 o0.001** 386 o0.001**
Non TN 314 33 298 9
TN 60 23 66 13
Significant P-values are in bold. *w
2 test; **, Fisher’s exact test. Nielsen groups: HER2 (HER2-positive, ER any, Ck5/6 or EGFR any), basal-like (HER2-negative, ER-negative, Ck5/6
or EGFR positive), luminal (HER2-negative, ER-positive, Ck5/6 or EGFR any). LVI, lymph vascular invasion. TN: Triple-Negative phenotype.
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breast cancers (Savage et al, 2007, 2008).
Given their distribution in normal breast, we assessed the
expression of CAV1 and CAV2 in a large population of invasive
breast cancer to determine whether they would be preferentially
expressed in the subgroup of breast carcinomas with myo-
epithelial/basal-like phenotype and their prognostic implications
in breast cancer.
This study highlights the link between CAV1 and CAV2 with the
myoepithelial/basal- and triple-negative groups of breast cancer.
The evidence for this comes from the correlation seen between
CAV1 and CAV2 and other conventional basal markers (Ck 14, Ck
5/6, and P-cadherin). Furthermore, positive CAV1 and CAV2
expression was associated with poor prognostic parameters
indicated by a poor Nottingham prognostic factor and high
histological grade. Conversely, cases with positive hormone
receptor status (ER and PR) and expressing luminal cytokeratins
(Ck 7/8, Ck 18 and Ck 19) showed negligible expression of CAV1
and CAV2, which is in agreement with previous studies (Hurlstone
et al, 1999; Charafe-Jauffret et al, 2006; Pinilla et al, 2006; Savage
et al, 2007, 2008). Therefore, it is not altogether surprising to find a
significant correlation between expression of caveolins 1 and 2 and
basal-like phenotype defined by Nielsen et al (2004) (40.5 and
66.7% of CAV1- and CAV2-positive cases, respectively) and the TN
phenotype (41.1 and 59.1% for CAV1- and CAV2-positive cases,
respectively).
Taken together, these data suggest that expression of CAV1 and
CAV2 is associated with basal-like phenotype in breast cancer.
This is in accordance with previous in situ studies, which
identified CAV1 and CAV2 genes as discriminators of the basal
phenotype, and address them as one of the underlying mechanism
driving CAV1 and CAV2 proteins overexpression in that group
(Perou et al, 2000; Charafe-Jauffret et al, 2006; Savage et al, 2007,
2008). However, in previous gene expression profiling studies
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Figure 2 Kaplan–Meier plots for CAV1 and CAV2 expression in invasive breast cancer. (A, B) Whole cohort regarding BCSS and MFS for CAV2. (C, D)
ER-negative cohort regarding DFS and BCSS with CAV1 and CAV2, respectively. (E) Low-grade cohort, the relation between CAV1 and DFS.
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to be expressed at higher levels in normal breast-like cancer.
Interestingly, unlike CAV1, the level of CAV2 mRNA was also
increased in the majority of basal-like cancer (Perou et al, 2000).
Moreover, a PCR study suggested downregulation of CAV1 and
CAV2 mRNA levels in non-microdissected breast cancer (Sagara
et al, 2004). It should be noted, however, that analysis of the
expression of caveolins 1 and 2 by expression array- and PCR-
based methods should be interpreted with caution, given that the
high levels of CAV1 and CAV2 reported in normal breast-like
samples (Perou et al, 2000; Sorlie et al, 2001) may derive from
stromal endothelial cells, fibroblast and adipocytes (Savage et al,
2007, 2008). Therefore, an accurate measurement of CAV1 and
CAV2 mRNA levels in neoplastic cells is not possible without
precise microdissection or by using in situ methods.
In this study, CAV1 expression was significantly associated with
a shorter BCSS in patients with low grade invasive breast cancers
whereas patients with CAV2-positive cancers had a shorter DFS.
These findings are supported by previous reports showing that
caveolin 1 and 2 expression is associated with highly aggressive
tumours such as inflammatory breast carcinoma (Eynden, 2005),
basal-like (Savage et al, 2007, 2008) and triple-negative breast
carcinoma (Shack et al, 2003; Tan et al, 2007; Savage et al, 2007,
2008). Aside from breast, the association between caveolin
expression and poor patient outcome was noticed in other tissue
tumours (Savage et al, 2007, 2008), including prostate (Karam
et al, 2007), lung ((Ho et al, 2008), and the central nervous system
(Barresi et al, 2006).
The mechanism underlying the expression of CAV1 and CAV2 in
breast cancer and specifically the basal-like phenotype is yet to be
determined. In a small proportion of basal-like breast cancers, this
seems to be driven by gene amplification (Savage et al, 2007, 2008).
Moreover, hypomethylation of CAV1 and CAV2 promoters may be a
possible cause (Engelman et al, 1999). However, the mechanism for
CAV1 and CAV2 expression in basal-like cancers may stem from
maintenance of a basal/myoepithelial phenotype or might be part of
a transcriptomic programme of myoepithelial/basal-like differentia-
tion, as these proteins are preferentially expressed in basal/
myoepithelial cells of normal breast.
In conclusion, our findings and those of other recently reported
studies show that CAV1 and CAV2 have oncogenic properties and
are associated with breast carcinomas of basal-like and triple
negative phenotypes. On univariate analysis, expression of
caveolins was significantly associated with high histological grade,
poor Nottingham Prognostic Index and with a more aggressive
clinical behaviour (i.e. CAV2 expression was associated with
shorter DFS in the whole cohort and CAV1 was associated with
short BCSS in the group of low grade tumours). However, on
multivariate analysis, both proteins were shown not to be
independent prognostic factors for DFS and BCSS. Further studies
are warranted to identify whether CAV1 and CAV2 play a role in
the biology of basal-like and triple-negative tumours, or if they are
mere surrogate markers for basal differentiation.
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